Mazdutide

Research use only: Mazdutide has not received FDA approval for human use. Information on this page is for research and educational purposes only and does not constitute medical advice or an endorsement to purchase for personal use.

Mazdutide is a synthetic peptide. It is an acylated, long-acting analog of the human hormone oxyntomodulin, designed as a dual agonist that acts on both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It acts as a therapeutic agent for obesity and type 2 diabetes by reducing appetite and increasing energy expenditure.

Key Benefits of Mazdutide Peptide

• May support significant weight loss by helping reduce appetite and calorie intake
• Commonly researched for improving blood sugar control and metabolic health
• May help support healthy fat loss while preserving lean body mass
• Research suggests potential benefits for cardiovascular and overall metabolic wellness support

FDA-Approved Uses

Mazdutide is under active clinical development in the US by Eli Lilly.

China NMPA approvals (Xinermei®)

Obesity / Weight Management (June 2025):

• World’s FIRST approved dual GLP-1/glucagon receptor agonist for obesity
• Indicated for adults with BMI ≥28 kg/m² or ≥24 kg/m² with weight-related comorbidity
• Type 2 Diabetes (September 2025):
• Approved as adjunct to diet and exercise for glycemic control in adults with T2DM

US FDA Development Timeline of Mazdutide

• Phase 1 (high-dose): Completed 2025 (doses up to 16 mg studied; Diabetes Obes Metab 2025)
• Phase 2 (US): Active enrollment (NCT06143956), ongoing
• Phase 3: Expected 2026–2027
• NDA/BLA submission: Estimated 2027–2028
• FDA decision: Estimated 2028–2029
• [If granted Priority Review as first dual GLP-1/GCGR agonist: possible 2027]

Conditions being studied About Mazdutide

• Obesity / Overweight (primary US indication under development)
• Type 2 Diabetes
• Metabolic dysfunction-associated fatty liver disease (MAFLD/MASLD)
• Cardiovascular outcomes (planned)

Mechanism distinction vs. existing GLP-1 drugs

• Semaglutide, liraglutide: GLP-1 receptor agonist only
• Tirzepatide: GLP-1 + GIP dual agonist
• Retatrutide: GLP-1 + GIP + glucagon triple agonist
• Mazdutide: GLP-1 + GLUCAGON dual agonist (different pairing from tirzepatide)

WADA status: Not on WADA Prohibited List

Mazdutide Peptide Trade Names in the USA and Manufacturers

China-approved brands of Mazdutide

• Xinermei® (mazdutide injection) – approved China NMPA June/September 2025
• Manufacturers: Innovent Biologics (Suzhou) Co. Ltd. / Innovent Biologics, Inc.
• Distributor in China: Eli Lilly and Company (partnership)

Developers of Mazdutide

• Originally developed by: Innovent Biologics (Suzhou) Co. Ltd. (China)
• Co-developed/licensed: Eli Lilly and Company (Indianapolis, IN, USA)
• Compound codes: IBI362 (Innovent) / LY3305677 (Eli Lilly)

US availability (as of May 2026)

• Phase 2 clinical trial (NCT06143956): Only legal supervised US access
• Importation of Xinermei® from China: Legally complex; not recommended without medical supervision
• Not available via US pharmacies, compounding, or telehealth for general use

Molecular identity of Mazdutide

• Long-acting GLP-1 and glucagon receptor (GCGR) dual agonist peptide
• Administered as once-weekly subcutaneous injection
• Fatty acid chain modification enables long half-life (~7 days) for weekly dosing
• Exact full sequence not publicly disclosed in available literature

Dosage of Mazdutide Peptide

China-approved dosing (Xinermei®):
Once-weekly subcutaneous injection with dose escalation:

Obesity indications of Mazdutide

• Weeks 1–4: 1 mg/week
• Weeks 5–8: 2 mg/week
• Weeks 9–12: 3 mg/week
• Week 13+: 4–6 mg/week (maintenance; max studied: 6 mg for obesity)

Type 2 Diabetes indication of Mazdutide

Similar escalation schedule; doses per physician judgment

US Phase 1 trial doses (research only – NOT approved):

Up to 16 mg/week studied (Diabetes Obes Metab, 2025 publication)

US Phase 2 trial doses (NCT06143956 – investigational):

Multiple doses under evaluation; results pending

Route: Subcutaneous injection, abdomen, thigh, or upper arm
Frequency: Once weekly (consistent with semaglutide and tirzepatide dosing schedules)
No dose adjustment required for mild-to-moderate renal impairment (based on dual GLP-1/GCGR profile)

Mazdutide Peptide Price

Mazdutide is a dual GLP-1 and glucagon receptor agonist. It is approved in China for weight management and type 2 diabetes. Many people search for “mazdutide peptide price” online. The results can be confusing. Prices vary widely depending on what you are buying. This guide explains the different types of mazdutide products and their costs.

Two Very Different Products

There is an important distinction to understand. Mazdutide is sold in two completely different forms. Each has its own pricing structure.

Research-grade Mazdutide peptide Price

This form is sold to laboratories for scientific study. It is not approved for human use. It comes as a powder for research purposes only. Prices for this form are relatively low.

Price of Pharmaceutical products Chemically Similar to Mazdutide

This is the approved medicine for patients. It is sold under the brand name Xinermei in China. It comes as a ready-to-use injection pen. Prices for this form are much higher.

Confusing these two products can lead to problems. Buying research-grade peptide for personal use is not safe or legal. The information below covers both categories so you can understand the full picture.

Research-Grade Mazdutide Prices

Many chemical suppliers sell mazdutide for laboratory research. These products are not for human consumption. Prices depend on the quantity and the supplier.

Here are some current prices from major suppliers:

• TargetMol: 1 mg costs $89. The 5 mg size costs $272. The 10 mg size costs $455. Larger sizes are also available: 25 mg for $736 and 50 mg for $1,172.
• GlpBio: 1 mg costs $88. The 5 mg size costs $264. The 10 mg size costs $440.
• AbMole: 1 mg costs $105. The 5 mg size costs $320. The 10 mg size costs $540.
• ApexBio: 1 mg costs $99. The 5 mg size costs $297. The 10 mg size costs $495.
• Cenmed: This supplier lists a price of $439.26 for their mazdutide product.

Chinese suppliers also list research-grade mazdutide. One supplier offers 1 mg for ¥880, 5 mg for ¥2,640, and 10 mg for ¥4,400. Another lists 1 mg at ¥913, 5 mg at ¥2,730, and 10 mg at ¥4,570.

These prices show a clear pattern. Buying in larger quantities reduces the cost per milligram. The 10 mg size is often the best value for laboratories that need a larger supply.

What Affects Research-Grade Mazdutide Prices

Several factors change the price of research-grade mazdutide.

Quantity: Larger sizes cost less per milligram. A 10 mg vial often costs less than two 5 mg vials.

Supplier: Prices vary between companies. Some suppliers charge more for faster shipping or higher purity standards.

Purity: Most research-grade peptides are at least 98% pure. Higher purity levels can increase the price.

Shipping: Some suppliers include shipping in the price. Others add it at checkout. This can affect the total cost significantly.

Mazdutide Like Pharmaceutical Product Price

The approved medicine for patients is sold in China. It is marketed by Innovent Biologics. Eli Lilly developed the drug, but Innovent holds the commercial rights in China.

The recommended monthly price for the maximum dose is 2,920 yuan. This is about $411 USD. This price puts mazdutide in line with Wegovy and lower than Mounjaro in the Chinese market.

This price is for a full month of treatment at the highest dose. Lower doses during the starting phase may cost less. The exact price can vary by pharmacy and region.

Market Position and Future Prices of Mazdutide

Mazdutide launched in China in July 2025. It is the third GLP-1 injection for obesity available in China. It follows Wegovy from Novo Nordisk and Mounjaro from Eli Lilly.

Market analysts predict strong sales. Morningstar estimates mazdutide could generate over 600 million yuan in 2025. That could reach 3.5 billion yuan by 2029. This would represent about 20% of Innovent’s revenue.

As competition increases, prices may change. More GLP-1 drugs entering the market could put downward pressure on prices. For now, mazdutide is positioned as a competitively priced option.

Important Safety Warning About Mazdutide

Research-grade mazdutide is sold for laboratory experiments only. It is not sterile. Mazdutide is not tested for human safety. It should never be injected or consumed.

The pharmaceutical product is only available through a prescription in China. It requires medical supervision. Mazdutide has serious side effects. These include nausea, vomiting, and rare but serious risks like pancreatitis.

Do not buy research-grade mazdutide for personal use. The low prices may seem attractive. But the risks to your health are not worth it. Wait for proper approval and talk to a doctor about safe treatment options.

Mazdutide peptide price varies hugely by product type. Research-grade peptide costs between $88 and $1,172 depending on quantity and supplier. The approved medicine costs about 2,920 yuan per month in China. It is not yet available in the US or most other countries. Do not use research-grade peptide for personal treatment. It is not safe. Talk to a doctor about approved options for weight management.

Tips

• Monitor Eli Lilly’s Phase 3 trial initiation (expected 2026–2027) and NDA submission (estimated 2027–2028). FDA priority review designation as the first dual GLP-1/GCGR agonist could accelerate the timeline to 2027.
• Mazdutide’s key differentiator from tirzepatide is the glucagon receptor component (vs. tirzepatide’s GIP component). Glucagon receptor activation increases energy expenditure and thermogenesis ; a different additional mechanism from GIP’s insulin-sensitizing effects.
• Patients in China with access to Xinermei® have the only current legitimate pharmaceutical access. Importation for personal use in the US is legally complex and not generally recommended.
• For US patients: The only supervised, legitimate US access is via clinical trial enrollment. Search ClinicalTrials.gov for ‘mazdutide’ or ‘LY3305677’ or ‘NCT06143956’.
• Side effect profile is consistent with the GLP-1 peptide medications (nausea, vomiting, GI effects) ; similar management strategies apply (slow dose escalation, eating habits, antiemetics if needed).

Side Effects of Mazdutide: What You Need to Know

Mazdutide is a newer medicine for type 2 diabetes and obesity. It works on two gut hormone receptors. These are GLP-1 and glucagon. This dual action helps control blood sugar and reduce appetite. But like many medicines, mazdutide can cause side effects. Most of these effects are mild. They often go away on their own. Still, it helps to know what to expect. This guide covers the common and rare side effects of mazdutide.

Why Mazdutide Causes Side Effects?

Mazdutide slows down how fast your stomach empties. It also changes how your brain signals hunger. These actions are the main reason side effects happen. The slowed stomach emptying can cause nausea and fullness. The brain signaling can cause appetite loss. These are not signs of harm to your organs. They simply show the drug is working. This is an important point to remember. It makes the early weeks easier to handle.

Common Side Effects of Mazdutide

Most people who take mazdutide will have some side effects. Studies show that 60 to 80 percent of patients get gastrointestinal symptoms. These are problems with the stomach and gut.

Nausea is the most common side effect. It often peaks in the first two to three days after a dose increase. It does not usually last all day. Vomiting can also happen. So can diarrhea or loose stools. Some people get constipation instead. This often shows up later, around weeks six to eight. That is when the body adjusts to slower digestion.

Other common effects include:

• Decreased appetite
• Fatigue
• Mild headache
• Injection site reactions like redness or itching
• A feeling of fullness that lasts a long time
• Acid reflux

These symptoms are often worse in the first month. They tend to fade as the body gets used to the drug.

When Mazdutide Side Effects Happen?

Mazdutide side effects follow a pattern. Most start within 24 to 48 hours of the first injection. They peak during weeks two to four. After that, they slowly improve. By weeks six to eight, most people feel much better.

Dose increases can bring symptoms back. This happens because the body must adjust to a higher level of the drug. These flare-ups are usually milder than the first time. They also go away faster.

Here is a simple timeline:

• Weeks 1 to 2: Nausea, vomiting, and diarrhea are most common here.
• Weeks 3 to 4: Nausea drops by about half. Bowel habits become more stable.
• Weeks 5 to 8: Only 20 to 30 percent of people still have mild symptoms. Constipation may appear now.
• Months 2 to 3: Most symptoms are gone. Mild symptoms may return briefly with each dose increase.

Knowing this timeline helps you prepare. It also helps you tell the difference between normal adjustment and a real problem.

Factors That Affect Your Experience During Mazdutide Therapies

Not everyone reacts the same way. Several things can change how bad your side effects are.

The speed of your dose increase matters most. A slower titration schedule can cut symptom severity by about 40 percent. Your age and overall health also play a role. Older adults often need more time to adjust. Other medicines can make gut symptoms worse. This is especially true for drugs that affect stomach emptying or blood sugar. Your diet matters too. Small, frequent meals can reduce nausea by up to 60 percent. High-fat foods tend to make symptoms worse.

Less Common but Serious Side Effects of Mazdutide

Most side effects are not dangerous. But a few rare ones need quick medical care.

Pancreatitis: This is a rare but serious risk with all GLP-1 drugs. Watch for severe belly pain that spreads to your back. Get medical help the same day if this happens.

Heart rate changes: Mazdutide can raise your resting heart rate. This comes from its glucagon receptor activity. Most cases are mild. But tell your doctor if your heart feels like it is racing. This is extra important if you also feel dizzy or have chest pain.

Low blood sugar: Mazdutide alone rarely causes low blood sugar. But the risk goes up if you also take insulin or sulfonylureas. Learn the signs of low blood sugar. These include shaking, sweating, and confusion.

Allergic reactions: Facial swelling, trouble breathing, or a widespread rash need emergency care right away.

Vision changes: Some GLP-1 drugs have been linked to vision problems. If your eyesight changes, see an eye doctor.

Liver enzyme changes: Early trials showed mild, short-term liver enzyme rises in a few people. A liver check before starting treatment is a good idea.

How Mazdutide Compares to Other GLP-1 Drugs

Mazdutide is not the same as semaglutide or tirzepatide. Semaglutide targets only GLP-1. Tirzepatide targets GLP-1 and GIP. Mazdutide targets GLP-1 and glucagon. This difference shapes its side effect profile.

Early nausea may be stronger on mazdutide. That is because of the glucagon action. Appetite suppression may also feel stronger. Constipation tends to show up around weeks six to eight. This is similar to other drugs in the class. Injection site reactions are usually mild. Heart rate increases are reported more often with mazdutide at higher doses.

How to Manage Mazdutide Side Effects?

You cannot fully prevent side effects. But you can make them easier to handle.

• Eat smaller meals more often.
• Avoid greasy, spicy, and high-fat foods.
• Stay hydrated throughout the day.
• Do not lie down right after eating.
• Follow your dose schedule exactly. Do not speed it up.
• Add fiber to your diet if you get constipated.
• Ask your doctor about a gentle stool softener if needed.
• Rotate your injection sites.
• Keep your protein and nutrient intake up, even if you are not hungry.

These simple steps can shorten your symptoms and make them less severe.

When to Call Your Doctor?

Contact your doctor right away if you have:

• Severe belly pain that spreads to your back
• A fast heartbeat with dizziness or chest pain
• Signs of an allergic reaction, like facial swelling or trouble breathing
• Vomiting that will not stop and keeps you from drinking fluids
• Unexplained vision changes
• Symptoms that get worse after the first month

Do not wait these out. Quick action can prevent serious problems.

The Bottom Line

Mazdutide side effects are common but usually manageable. Most are gastrointestinal and peak in the first few weeks. They improve as your body adapts. By weeks six to eight, most people feel much better. A small number of serious effects need prompt care. Know the red flags. Follow your titration schedule. Make smart food and fluid choices. With these steps, most people can stay on treatment and get the full benefits of mazdutide.

Always talk to your doctor about your personal risks. This article is for information only. It is not a substitute for medical advice.

Pharmacology of Mazdutide

Mazdutide (IBI362 / LY3305677) is a synthetic, long-acting peptide dual agonist of two receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It was developed by Innovent Biologics (China) in collaboration with Eli Lilly and Company.

Key Pharmacological Distinction

• GLP-1R + GIP receptor (tirzepatide, retatrutide): This pairing leverages insulin secretion enhancement (GIP) + appetite suppression (GLP-1)
• GLP-1R + GCGR (mazdutide): This pairing leverages energy expenditure increase (glucagon) + appetite suppression (GLP-1), a different complementary mechanism

Half-life enabling once-weekly dosing

Engineered with fatty acid chain modification enabling albumin binding and extended half-life of approximately 7 days, same strategy as semaglutide (Ozempic/Wegovy).

Mechanism of action Mazdutide

GLP-1 Receptor Activation (shared mechanism with semaglutide):

• Glucose-dependent insulin secretion from pancreatic beta cells
• Glucagon suppression from alpha cells
• Slowed gastric emptying
• Hypothalamic appetite suppression (reduced caloric intake)
• Weight loss primarily via reduced food intake

Glucagon Receptor (GCGR) Activation (unique addition vs. semaglutide)

• Increases hepatic glucose output (acutely; balanced by GLP-1’s insulin effect)
• Increases energy expenditure via thermogenesis (brown adipose tissue activation)
• Promotes lipolysis in fat tissue (direct fat-burning effect)
• Reduces liver fat (hepatic lipid metabolism improvement, basis for MAFLD indication)

Net metabolic effect: Greater energy expenditure + fat oxidation on top of GLP-1’s appetite suppression → enhanced weight loss vs. GLP-1 alone

Dual agonism balance:
The opposing glucose effects (GLP-1 lowers, GCGR raises) are carefully balanced in the designed molecule to produce favorable glycemic control overall, while the weight-loss effects are additive (both pathways reduce body weight through different mechanisms).

Result Claims from Different Companies

Innovent Biologics / Eli Lilly (based on published clinical trial data):

Phase 2 (Nature Communications, 2023 – Chinese adults)

Doses: 3 mg, 4.5 mg, 6 mg vs. placebo; 24 weeks
Body weight reductions: Statistically significant at all doses vs. placebo
Well-tolerated; no serious safety signals
Primary endpoint (% body weight change at week 24) met

Phase 1 high-dose trial (Diabetes Obes Metab, Aug 2025 – Eli Lilly led, US-based)

• Doses up to 16 mg/week tested
• Statistically significant weight reductions vs. placebo
• Safety profile consistent with GLP-1 drug class
• Published by Melissa K. Thomas et al. (Eli Lilly)

Phase 3 GLORY-1 (NEJM publication)

• 4 mg or 6 mg once-weekly for 32 weeks in Chinese adults with overweight/obesity
• ‘Clinically relevant reductions in body weight’ vs. placebo
• NMPA approval for obesity based on this and supporting data

⚠️ US Phase 3 data pending. All efficacy data from Chinese populations. Cross-population generalizability to Western populations requires confirmation in ongoing/planned US Phase 3 trials. FDA will require US or global trial data for NDA approval.

Mazdutide vs Retatrutide

Mazdutide and retatrutide are two new medicines for weight loss and diabetes. Both are injectable drugs. Both target gut hormones. But they work in different ways. This guide compares them side by side.

Mazdutide vs Retatrutide Differences in Mechanism

The two drugs target different receptors in the body.

Mazdutide is a dual agonist. It targets two receptors: GLP-1 and glucagon . This dual action helps control blood sugar and reduce appetite.

Retatrutide is a triple agonist. It targets three receptors: GLP-1, GIP, and glucagon. The extra GIP receptor may add more weight loss power.

This difference matters. More receptors do not always mean a better drug. But early data suggest the triple action of retatrutide leads to greater weight loss.

Weight Loss Results : Mazdutide vs Retatrutide

Clinical trials show a clear difference in weight loss between the two drugs.

Mazdutide

results from a phase 3 trial in Chinese adults with obesity: At 60 weeks, patients on mazdutide 9 mg lost an average of 16.65% of their body weight. A separate report noted a mean reduction of 18.55%. About 44% of patients lost at least 20% of their weight.

Retatrutide

results from a phase 3 trial in adults with obesity: At 80 weeks, patients on retatrutide 12 mg lost an average of 25.0% of their body weight. At the 9 mg dose, the reduction was 23.7% . In a separate trial of patients with type 2 diabetes, retatrutide 12 mg led to an average weight loss of about 17% over 10 months .

A network meta-analysis compared the two drugs directly. Retatrutide showed a mean weight reduction of 13.44 kg versus placebo. Mazdutide showed a mean reduction of 6.47 kg. This analysis ranked retatrutide highest for weight loss efficacy.

The bottom line: Retatrutide appears to produce greater weight loss than mazdutide. But the trials studied different populations and used different time points.

Blood Sugar Control : Mazdutide vs Retatrutide

Both drugs improve blood sugar. The data again favor retatrutide.

In patients with type 2 diabetes, mazdutide 6 mg reduced HbA1c by 2.15% at 24 weeks .

Retatrutide showed HbA1c reductions of up to 1.50% at 80 weeks in a diabetes trial. Another report noted reductions up to 2%. The network meta-analysis found retatrutide had the largest effect on HbA1c, though only its effect reached statistical significance.

Side Effects and Tolerability

This is where mazdutide may have an advantage. The same network meta-analysis found mazdutide had the most favorable tolerability profile. Retatrutide was associated with lower tolerability.

Discontinuation rates tell a similar story. Mazdutide had the lowest rate of stopping treatment due to side effects. Retatrutide had the highest .

Both drugs cause gastrointestinal side effects. These include nausea, vomiting, and diarrhea. In the mazdutide trial, vomiting occurred in 53.1% of patients, nausea in 46.9%, and diarrhea in 39.4%. Retatrutide also commonly causes these effects.

For vomiting, mazdutide had a slightly less favorable profile than retatrutide in one analysis. For nausea, retatrutide had the least favorable profile among the drugs studied.

Mazdutide can also raise heart rate at higher doses. This effect is usually mild and transient. Retatrutide may cause similar effects, though data are still emerging.

Approval Status

This is a major practical difference.

• Mazdutide is approved in China. It received approval for weight management. It is sold under the brand name Xinermei. It is not approved in the US or most other countries.
• Retatrutide is not approved anywhere. It remains an investigational drug in clinical trials. Eli Lilly is running phase 3 trials. Approval may come in the future, but no timeline is certain.

The TGA in Australia issued a safety alert about counterfeit retatrutide. Testing found a product sold as retatrutide contained no retatrutide. Instead, it had semaglutide at eight times the normal dose. One person suffered a torn oesophagus from uncontrollable vomiting.

Cost and Availability Mazdutide vs Retatrutide

Mazdutide is available in China through a prescription. The price for a month at the maximum dose is about 2,920 yuan (roughly $411 USD).

Retatrutide has no approved price. It is only available through clinical trials. Any product sold online as retatrutide is counterfeit and dangerous .

Mazdutide vs Retatrutide: Which One Is Better?

There is no simple answer. It depends on what you value most.

• If you want the greatest weight loss, retatrutide appears stronger based on current data. But it is not approved and not available.
• If you want a drug that is approved and has better tolerability, mazdutide may be the better choice. It is available in China.

Both drugs are new. Long-term safety data are still limited. More trials will help clarify the full picture.

Mazdutide and retatrutide are both new injectable drugs for weight loss and diabetes. Retatrutide targets three receptors and shows greater weight loss in trials. Mazdutide targets two receptors and has better tolerability. Mazdutide is approved in China. Retatrutide is still in trials and not approved anywhere. Counterfeit retatrutide has caused serious harm. Always use approved medicines under medical supervision.

Mazdutide vs Tirzepatide

Mazdutide and tirzepatide are both injectable medicines for weight loss and type 2 diabetes. Both target gut hormone receptors. But they work in different ways. This guide compares them side by side.

Mazdutide vs Tirzepatide : How They Work

The two drugs target different receptors in the body.

Mazdutide is a dual agonist. It targets two receptors: GLP-1 and glucagon. This dual action helps control blood sugar and reduce appetite. The glucagon part may also help the body burn more energy.

Tirzepatide is also a dual agonist. But it targets different receptors: GLP-1 and GIP. The GIP receptor may add extra weight loss power. It may also reduce nausea compared to GLP-1 alone.

This difference matters. Both drugs activate two receptors. But the specific receptors are not the same.

Weight Loss Results Mazdutide vs Tirzepatide

Clinical trials show tirzepatide produces more weight loss than mazdutide. But these results come from different studies. There is no direct head-to-head trial comparing the two drugs.

Tirzepatide results from major trials: In the SURMOUNT-1 trial, patients lost up to 20.9% of their body weight at 72 weeks. In the SURPASS trials for diabetes, weight loss ranged from 9.5 kg to 12.9 kg depending on the dose and comparison group.

Mazdutide results from phase 3 trials in Chinese adults: At 48 weeks, patients on the 6 mg dose lost an average of 14.01% of their body weight. Other reports noted weight loss up to 18.6% over 24 to 60 weeks across different trials.

A network meta-analysis compared the two drugs indirectly. Tirzepatide ranked higher than mazdutide for weight loss. The analysis gave tirzepatide a p-score of 0.90 for body weight reduction. Mazdutide received a p-score of 0.31.

The bottom line: Tirzepatide appears to produce greater weight loss. But the trials studied different populations. The mazdutide trials focused on Chinese adults.

Blood Sugar Control

Both drugs improve blood sugar. The data again favor tirzepatide.

In the SURPASS trials, tirzepatide reduced HbA1c by up to 2.59% at 40 to 42 weeks. A separate meta-analysis confirmed tirzepatide reduces HbA1c by 1.13% compared to placebo.

Mazdutide has also shown strong results. In a phase 3 trial, mazdutide 6 mg reduced HbA1c by 2.15% at 24 weeks in patients with type 2 diabetes.

A comprehensive clinical evaluation noted that tirzepatide has a “high-efficacy, high-cost” profile. Mazdutide’s main limitation is its immature evidence base. It lacks published phase 3 results in some areas and has less cardiovascular outcomes data.

Side Effects and Tolerability

Both drugs cause gastrointestinal side effects. These include nausea, vomiting, diarrhea, and constipation. These effects are most common during dose increases.

Tirzepatide has an FDA boxed warning about a possible risk of thyroid C-cell tumors. This warning comes from animal studies. It is not known if the drug causes this in humans.

Mazdutide’s full global safety picture is still developing. It is approved in China. But long-term safety data are still limited.

One analysis suggested the GIP receptor action in tirzepatide may reduce nausea compared to GLP-1 alone. But both drugs still commonly cause GI side effects.

Approval Status and Availability

This is a major practical difference.

Tirzepatide is FDA approved. It is sold as Mounjaro for type 2 diabetes and Zepbound for weight management. Tirzepatide is available in the US and many other countries. It was the most prescribed weight management medication in 2025.

Mazdutide is approved only in China. It received approval for weight management and type 2 diabetes. Mazdutide is sold under the brand name Xinermei. It is not approved by the FDA. It is not available in the US.

Cost and Price

Tirzepatide costs vary widely in the US. The list price for Zepbound is about $1,059 per month. But cash-pay programs offer lower prices. LillyDirect sells single-dose vials starting at $299 per month for the 2.5 mg starter dose.

Mazdutide costs much less in China. A year of treatment at maintenance dose costs roughly $1,300 to $2,000 USD out of pocket. That is the total for 52 weeks. It is not available in the US.

A clinical evaluation noted that both tirzepatide and mazdutide are not on China’s National Reimbursement Drug List. Patients must pay entirely out of pocket.

Mazdutide vs Tirzepatide Which One Is Better?

There is no simple answer. It depends on where you live and what you need.

• If you are in the US, tirzepatide is your only option. Mazdutide is not available.
• Anyone Looking the greatest weight loss, tirzepatide appears stronger based on current data.
• If cost is the main concern and you live in China, mazdutide may be more affordable.

Both drugs are effective. Both have similar side effect profiles. Tirzepatide has more long-term safety data because it has been approved longer.

Disclaimer

This content about “Mazdutide (IBI362 / LY3305677) Dual GLP-1 / Glucagon Receptor Agonist” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.